cagrilintide fda (10mg vials) cagrilintide

Our reference on the cagrilintide-and-semaglutide combination in obesity research keeps the two apart

Cagrilintide as a stand-alone drug has been studied through Phase 2, [1] but most of the headline cagrilintide numbers people cite actually come from CagriSema the fixed-dose combination of cagrilintide 2.4 mg with semaglutide 2.4 mg which advanced into the Phase 3 REDEFINE program

These experiments confirmed that cagrilintide is a potent dual agonist, activating both receptor types, which is crucial for its therapeutic effect on reducing food intake and body weight, as demonstrated in preclinical rat models

Cagrilintide monotherapy remains investigational, and the CagriSema combination although it has been submitted for regulatory review remained unapproved as of this writing

doi:10.1016/S0140-6736(21)00845-X

PMID 40544432